The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Not Applicable
Recruiting
- Conditions
- HER2-positive Breast Cancer
- Interventions
- Diagnostic Test: GeoMx data analysis with clinical outcome
- Registration Number
- NCT06330012
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
- HER2 positive breast cancer
- Stage IV disease
- Treated with T-Dxd
- Available FFPE samples
Exclusion Criteria
- TNBC breast cancer
- Hormone receptor positive breast cancer
- Non-available FFPE samples
- Treated except T-Dxd
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Spatial transcriptomic approch GeoMx data analysis with clinical outcome Spatial transcriptomic approch for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
- Primary Outcome Measures
Name Time Method Spatial transcriptomic analysis Before chemotherapy, curative surgery Protein expression and relationship protein-protein in HER2 positive breast cancer tumor cells and tumor microenvironment.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ji-Yeon Kim
🇰🇷Seoul, Korea, Republic of